The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1109
July 23, 2001
View Complete Issue         Table of Contents 2019 
Oral Balsalazide (Colazal) For Ulcerative Colitis
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Oral Balsalazide (Colazal) For Ulcerative Colitis
July 23, 2001 (Issue: 1109)
Balsalazide disodium (Colazal), a prodrug of mesalamine, was marketed in the US this year for oral treatment of mildly to moderately active ulcerative colitis. Oral formulations of mesalamine have been available in the US for nine years for treatment...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Oral Balsalazide (Colazal) For Ulcerative Colitis
Article code: 1109b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.